Cargando…
The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China
Recently, the Benefit Finding Scale (BFS) has been translated and culturally adapted for use in China. However, further validation of the instrument is required before it can be used in the management of patients with cervical cancer in China. In this study, we conducted the questionnaire survey and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371820/ https://www.ncbi.nlm.nih.gov/pubmed/36017019 http://dx.doi.org/10.1155/2022/8977011 |
_version_ | 1784767243673927680 |
---|---|
author | Peng, Zhouyuan Liu, Ke Zhang, Yuting Hong, Qingyu Sun, Liyuan |
author_facet | Peng, Zhouyuan Liu, Ke Zhang, Yuting Hong, Qingyu Sun, Liyuan |
author_sort | Peng, Zhouyuan |
collection | PubMed |
description | Recently, the Benefit Finding Scale (BFS) has been translated and culturally adapted for use in China. However, further validation of the instrument is required before it can be used in the management of patients with cervical cancer in China. In this study, we conducted the questionnaire survey and examined its properties. This methodological study was conducted at a tumor hospital located in southwestern China. Patients with cervical cancer who had been reexamined in the outpatient department of the hospital and hospitalized from June to August 2019 were selected. The item analysis, exploratory factor analysis (EFA), and reliability analysis were tested. The relationships between benefit finding and sociodemographic and disease-related variables were analyzed by ANOVA and regression models. A total of 247 patients were assessed (mean age: 48.0 ± 13.3 years). Educational level, self-perceived disease severity, and physical exercise were the predictors of benefit finding. The correlation coefficient between 22 items and their dimensions was the best. EFA analysis supported a five-factor model for structure validity. All Cronbach's alpha for the Chinese version of the BFS (BFS-C) was greater than 0.80. The results demonstrated the good reliability and validity of BFS-C. It appears to be a useful scale to assess experience of benefit finding among patients with cervical cancer in China. |
format | Online Article Text |
id | pubmed-9371820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-93718202022-08-24 The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China Peng, Zhouyuan Liu, Ke Zhang, Yuting Hong, Qingyu Sun, Liyuan Contrast Media Mol Imaging Research Article Recently, the Benefit Finding Scale (BFS) has been translated and culturally adapted for use in China. However, further validation of the instrument is required before it can be used in the management of patients with cervical cancer in China. In this study, we conducted the questionnaire survey and examined its properties. This methodological study was conducted at a tumor hospital located in southwestern China. Patients with cervical cancer who had been reexamined in the outpatient department of the hospital and hospitalized from June to August 2019 were selected. The item analysis, exploratory factor analysis (EFA), and reliability analysis were tested. The relationships between benefit finding and sociodemographic and disease-related variables were analyzed by ANOVA and regression models. A total of 247 patients were assessed (mean age: 48.0 ± 13.3 years). Educational level, self-perceived disease severity, and physical exercise were the predictors of benefit finding. The correlation coefficient between 22 items and their dimensions was the best. EFA analysis supported a five-factor model for structure validity. All Cronbach's alpha for the Chinese version of the BFS (BFS-C) was greater than 0.80. The results demonstrated the good reliability and validity of BFS-C. It appears to be a useful scale to assess experience of benefit finding among patients with cervical cancer in China. Hindawi 2022-08-04 /pmc/articles/PMC9371820/ /pubmed/36017019 http://dx.doi.org/10.1155/2022/8977011 Text en Copyright © 2022 Zhouyuan Peng et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Peng, Zhouyuan Liu, Ke Zhang, Yuting Hong, Qingyu Sun, Liyuan The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China |
title | The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China |
title_full | The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China |
title_fullStr | The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China |
title_full_unstemmed | The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China |
title_short | The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China |
title_sort | 22-item benefit finding scale: validation and application among patients with cervical cancer in ethnic minority areas of southwestern china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371820/ https://www.ncbi.nlm.nih.gov/pubmed/36017019 http://dx.doi.org/10.1155/2022/8977011 |
work_keys_str_mv | AT pengzhouyuan the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT liuke the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT zhangyuting the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT hongqingyu the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT sunliyuan the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT pengzhouyuan 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT liuke 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT zhangyuting 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT hongqingyu 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina AT sunliyuan 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina |